Rockville, MD, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Based on a new research report published by Fact.MR, the global orally disintegrating tablet market is poised to reach a valuation of US$ 24.45 billion ...

Dublin, Feb. 06, 2024 (GLOBE NEWSWIRE) -- The "Orally Disintegrating Tablet Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, ...

An Increase in Demand and Opportunities for the Global Orally Disintegrating Tablet Market by 2024,” offers a comprehensive analysis of the market by evaluating research and information from multiple ...

A US Food and Drug Administration guidance issued Tuesday provides new recommendations to applicants who wish to designate proposed products as orally disintegrating tablets (ODTs). Rockville, MD (Dec ...

Pharmaceutical testing is a must to ensure that all medications meet the top quality, safety, and performance requirements before they enter the market. CD Formulation’s cGMP-compliant laboratory is ...

Offering a simple set-up specifically for vaginal tablets, the new tester reduces equipment investment costs relative to those associated with generic suppository testing, while at the same time ...

This article is part of PharmTech's supplement "API Synthesis and Formulation 2009." New drug-delivery technologies are often championed by contract manufacturing organizations. For new technologies ...

Please provide your email address to receive an email when new articles are posted on . The FDA recently approved Adzenys XR-ODT for the treatment of attention ...

Objective: To compare the flavour and taste preferences of two acid-inhibitory therapies in children. Subjects and Setting: 104 (52 male and 52 female) healthy children aged 6-11 years participated in ...

Neos Therapeutics Inc. recently announced the FDA approved Cotempla XR-ODT, an extended-release orally disintegrating tablet, for the treatment of ADHD in children aged 6 to 17 years. “Cotempla XR-ODT ...